$ News

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners may be pleased with recent gains after 28% loss over the past year

2 Penny Stocks That Wall Street Believes Can Soar Over 200%

Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration

Trexquant Slashes Stake in Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies: Q2 Earnings Snapshot

Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Reversal Of Fortune For Adverum Biotechnologies Insiders Who Made A US$526.8k Purchase

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

3 US Penny Stocks With Market Caps Below $400M